NCT02446340View on ClinicalTrials.gov

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

dalazatide

Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

DRUG

placebo

Placebo delivered via subcutaneous administration twice per week for a total of 9 doses

Trial Locations (1)

66219

PRA International, Lenexa

Sponsors

Lead Sponsor

Kineta Inc.
All Listed Sponsors
lead

Kineta Inc.

INDUSTRY